Nivolumab Improves Survival in Relapsed Mesothelioma
Nivolumab Improves Survival in Relapsed Mesothelioma In the first ever placebo-controlled phase 3 trial in patients with relapsed mesothelioma, immunotherapy with nivolumab (Opdivo) significantly improved both overall survival (OS) and progressio ...